Financial Performance - The company reported a profit distribution plan of 2.00 RMB per 10 shares (including tax) based on a total of 1,114,117,970 shares[2]. - The company's operating revenue for 2023 was ¥3,355,070,109.54, representing an increase of 11.27% compared to the adjusted revenue of ¥3,015,294,339.82 in 2022[13]. - The net profit attributable to shareholders for 2023 was ¥295,111,611.86, which is a 6.51% increase from the adjusted net profit of ¥277,072,545.74 in 2022[13]. - The net profit attributable to shareholders after deducting non-recurring gains and losses reached ¥242,121,310.79, a significant increase of 153.20% from ¥95,623,162.63 in 2022[13]. - The net cash flow from operating activities for 2023 was ¥449,578,350.12, showing a remarkable increase of 375.51% compared to ¥94,546,036.93 in 2022[13]. - The total assets at the end of 2023 amounted to ¥6,652,886,075.81, reflecting a growth of 10.01% from ¥6,047,547,257.74 at the end of 2022[14]. - The net assets attributable to shareholders increased by 37.70% to ¥4,179,894,703.93 in 2023 from ¥3,035,582,436.43 in 2022[14]. - The company reported a basic earnings per share of ¥0.27 for 2023, up 3.85% from ¥0.26 in 2022[13]. - The weighted average return on equity for 2023 was 9.19%, a slight decrease of 0.29% from 9.48% in 2022[13]. Corporate Governance - The company emphasizes the importance of accurate financial reporting and has ensured that all board members attended the meeting to review the annual report[2]. - The company has established a comprehensive governance structure, ensuring compliance with relevant laws and regulations, and maintaining operational independence[102]. - The financial department operates independently, ensuring proper financial management and compliance with tax obligations without reliance on the controlling shareholder[105]. - The company held a total of five board meetings during the reporting period, with significant resolutions disclosed on various dates[120]. - The board of directors is actively involved in overseeing the company's strategic direction and performance metrics[120]. - The company maintained a high level of governance, with independent directors reviewing major transactions and fundraising activities to protect shareholder interests[126]. - The company plans to continue expanding its market presence and developing new products and technologies in the upcoming periods[126]. Risk Management - The company is committed to addressing potential risks and has outlined measures in the management discussion and analysis section of the report[2]. - The company has undergone changes in accounting policies due to new regulations effective from January 1, 2023, impacting financial reporting[14]. Research and Development - The company has a total of 46 ongoing formulation projects, including 24 innovative drugs, 2 modified new drugs, and 20 generic drugs[42]. - The company has established a comprehensive drug development platform focusing on specific disease areas, including perioperative, oncology, metabolic diseases, autoimmune, and respiratory diseases[29]. - The company has developed several key technology platforms, including an analysis testing platform and a compound screening platform, to support drug research and development throughout the entire cycle[34]. - The company is advancing several key R&D projects, including HSK7653 for type 2 diabetes treatment, which is expected to be approved for market[64]. - The company has received clinical trial approval for new indications for HSK31679, including "non-alcoholic fatty liver disease," with ongoing Phase II clinical trials[44]. Market Expansion - The company is actively pursuing international expansion, with two Phase III clinical trials for HSK3486 completed in the United States, preparing for NDA submission[25]. - The company aims to enhance market penetration for 环泊酚注射液 by leveraging its inclusion in the national medical insurance system in 2024, focusing on the ICU market[98]. - The company is preparing for the launch of 思美宁 and 倍长平, with a focus on multi-channel marketing and improving patient accessibility[99]. Environmental Responsibility - The company has not reported any significant environmental protection issues or been classified as a key pollutant discharge unit by environmental authorities[151]. - The company has implemented strict compliance with environmental laws and regulations across all subsidiaries[162]. - The company has achieved a 100% operational rate for its environmental protection facilities, ensuring compliance with pollutant discharge permits[177]. Employee Management - The total number of employees at the end of the reporting period was 5,448, with 4,801 from major subsidiaries and 647 from the parent company[131]. - The company implemented a competitive compensation management system to enhance employee retention and attract talent, focusing on performance-based incentives[133]. - The company emphasized talent development through various training programs and an online learning platform, enhancing overall employee quality[134]. Shareholder Engagement - The company will consider shareholder opinions and independent directors' input when proposing profit distribution plans[186]. - The company has a long-term commitment to distribute profits through cash or stock dividends, ensuring compliance with legal and operational requirements[182]. Strategic Focus - Haisco Pharmaceuticals plans to focus on unmet clinical needs and aims to become a leading brand in innovative drugs within five years[94]. - The company aims to enhance its integrated operational model, including compliance, talent development, and data systems[94]. - The company is concentrating on therapeutic areas such as perioperative anesthesia, diabetes, and oncology for sustained growth[94].
海思科(002653) - 2023 Q4 - 年度财报